Clinical Trials
17 trialsNCT00408590 2024-01-16
Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Mayo Clinic
Phase 1 Completed
NCT00989651 2021-10-20
Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01074411 2019-08-09
Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00079430 2019-07-22
Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00085358 2019-07-22
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
National Cancer Institute (NCI)
Phase 1 Completed
NCT00060359 2015-05-08
Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 1 Completed
NCT00006981 2015-04-30
Immunotoxin Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00066651 2015-04-30
Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00814086 2014-12-31
Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
GOG Foundation
Phase 1 Completed
NCT01294293 2014-12-25
TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
GOG Foundation
Phase 1 Completed
NCT00006235 2013-07-09
Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT00003380 2013-06-10
Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer
GOG Foundation
Phase 1 Terminated
NCT00003385 2013-05-27
Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 1 Completed
NCT00003967 2013-05-27
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 1 Completed
NCT00005026 2013-05-27
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Phase 1 Completed
NCT00002913 2013-01-24
Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00002977 2010-09-15
Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission
Fred Hutchinson Cancer Center
Phase 1 Completed